Marathon Money Podcast - Roll With Marathon Money and Win the Stock Market Race · Marathon Money Podcast - Roll With Marathon Money and Win the Stock Market Race

Maria Zannes CEO of bioAffinity Technologies BIAF Talks Early Lung Cancer Detection

·33 min·2 clips

Maria says BioAffinity has four case studies detecting lung cancer at stage 1A.

1. Marathon Money Podcast focuses on Maria Zannes and BioAffinity Technologies, with the episode centered on CYPATH lung and early lung cancer detection. 2. Kenny Coins hosts Maria Zannes, the CEO of BioAffinity Technologies, because she leads the company behind the BIAF ticker and CYPATH lung test. 3. The episode asks whether a non-invasive sputum test can change how doctors screen high-risk patients and decide what to do after a lung nodule appears. 4. Zannes says her father died of lung cancer at 39 after returning from World War II and smoking Lucky Strikes, which she uses to frame the stakes. 5. She says CYPATH lung is for people 50 to 80 years old with a 20 pack-year smoking history, especially those who have smoked within the last 15 years. 6. Kenny describes the test as a way to detect the smallest form of cancer before it grows, while Zannes says the result helps doctors avoid waiting or moving straight to invasive biopsy. 7. Zannes explains that patients collect sputum at home with a small kit, use a FedEx return label on day three, and send the sample to the lab overnight. 8. She says the lab processes the sample into a single-cell suspension, labels it with antibodies and probes, and uses a machine-learned algorithm to classify cell populations. 9. Zannes says the algorithm weighs three cell populations plus age and returns both a likely malignant or unlikely malignant answer and a probability score. 10. She says the company has four case studies detecting lung cancer at stage 1A and describes one patient who was treated without biopsy because of comorbidities. 11. Zannes says the test is reimbursed, had only reached the market a couple of years earlier, and saw its reimbursement begin in the last year. 12. She says the company expanded from Texas into the VA and federal supply schedule, then into the southeast, northeast, mid-Atlantic, and south. 13. Zannes says pulmonologists were the key opinion leaders at first, but family practitioners and internists are now using the test to triage patients with nodules. 14. She says physicians can use CYPATH lung to decide whether to move a patient sooner, since some specialists cannot see someone for three months. 15. Zannes cites a study by Dr. Sheila Habib and Dr. Michael Morris that modeled 2022 low-dose CT patients with indeterminate nodules. 16. She says that model found more than $2,700 savings per Medicare patient and $6,500 per private-insurance patient if CYPATH lung had been used. 17. The conversation is direct, investor-facing, and practical, with Kenny interrupting to ask about reimbursement, adoption, and government use. 18. Zannes speaks in a clinical but accessible style, using examples like sputum, phlegm, acapella, and stage 1A to explain the science. 19. People interested in lung cancer screening, medical diagnostics, and small-cap healthcare names would likely follow this episode. 20. People looking for entertainment, general market commentary, or non-medical topics would probably skip it.

Listen to the show on

Apple Podcasts Spotify

Play clips from this episode More from Marathon Money Podcast - Roll With Marathon Money and Win the Stock Market Race